Paul Rubin, MD
Paul leads the clinical development of BIOAGE's pipeline of therapies that target aging. Paul is an experienced pharma and biotech executive with extensive experience in small molecules, biologics and oligonucleotide therapeutics and has advanced dozens of compounds from discovery through approval. He has worked in multiple therapeutic areas where he was intimately involved with discovery, preclinical and clinical development, regulatory and marketing. Prior to joining BIOAGE, Paul was Executive VP Research and Development at miRagen from 2016-2020. He was Senior VP of Research and Development and CMO at XOMA. Ltd from 2011 – 2015, CEO of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009, and President and CEO of Critical Therapeutics, Inc. from 2002 to 2007. From 1996 to 2002, Dr. Rubin was associated with Sepracor, where he served as Senior VP, Development, and later as Executive VP, Research & Development. He was responsible for leading the successful development of many of Sepracor’s internally developed and approved products including Xopenex®, Lunesta®, Xopenex HFA® and Brovana®. From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, most recently as VP of Worldwide Clinical Pharmacology and Early Clinical Development. He was associated with Abbott from 1987 to 1993, including as VP, Immunology and Endocrinology, where he successfully advanced zileuton, the first and only approved 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma. Dr. Rubin received a BA from Occidental College and his M.D. from Rush Medical College. He is board certified in internal medicine completing his post-graduate training at the University of Wisconsin Hospital and Clinics.